-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the CDE official website shows that the Jiangsu Provincial Institute of Traditional Chinese Medicine has obtained the implied license for clinical trials for the total psoralen capsules declared as a new drug of category 1.
2 of traditional Chinese medicine
.
According to the data from Minet.
com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
.
2 of traditional Chinese medicine
.
According to the data from Minet.
com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
.
Source: CDE official website
Psoralea total glycosides capsule is a new orthopaedic traditional Chinese medicine.
It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
), which has the effect of warming kidney and helping yang.
Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
.
It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
), which has the effect of warming kidney and helping yang.
Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
.
According to the data of Minet.
com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
.
com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
.
Class 1 new drugs of traditional Chinese medicine for the musculoskeletal system declared for marketing/clinical in 2020
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to data from Minet.
com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
in China will exceed 30 billion yuan .
com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
in China will exceed 30 billion yuan .
In the Chinese patent medicine terminal of physical pharmacies in Chinese cities, it is expected that in 2021, the sales volume of five categories of drugs will exceed 10 billion yuan, and the musculoskeletal system Chinese patent medicine is one of them
.
.
2021E Top 5 products of Chinese patent medicines for musculoskeletal system in Chinese urban physical pharmacies
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
Judging from the ranking of Chinese patent medicine products in the musculoskeletal system, the total market share of TOP5 products exceeds 30%, of which Shujin Jianyao Pills topped the list with sales of over 1 billion yuan
.
.
Recently, the CDE official website shows that the Jiangsu Provincial Institute of Traditional Chinese Medicine has obtained the implied license for clinical trials for the total psoralen capsules declared as a new drug of category 1.
2 of traditional Chinese medicine
.
According to the data from Minet.
com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
.
2 of traditional Chinese medicine
.
According to the data from Minet.
com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
.
Source: CDE official website
Psoralea total glycosides capsule is a new orthopaedic traditional Chinese medicine.
It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
), which has the effect of warming kidney and helping yang.
Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
.
It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
), which has the effect of warming kidney and helping yang.
Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
.
According to the data of Minet.
com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
.
com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
.
Class 1 new drugs of traditional Chinese medicine for the musculoskeletal system declared for marketing/clinical in 2020
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to data from Minet.
com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
in China will exceed 30 billion yuan .
com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
in China will exceed 30 billion yuan .
In the Chinese patent medicine terminal of physical pharmacies in Chinese cities, it is expected that in 2021, the sales volume of five categories of drugs will exceed 10 billion yuan, and the musculoskeletal system Chinese patent medicine is one of them
.
.
2021E Top 5 products of Chinese patent medicines for musculoskeletal system in Chinese urban physical pharmacies
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
Judging from the ranking of Chinese patent medicine products in the musculoskeletal system, the total market share of TOP5 products exceeds 30%, of which Shujin Jianyao Pills topped the list with sales of over 1 billion yuan
.
.
Recently, the CDE official website shows that the Jiangsu Provincial Institute of Traditional Chinese Medicine has obtained the implied license for clinical trials for the total psoralen capsules declared as a new drug of category 1.
2 of traditional Chinese medicine
.
According to the data from Minet.
com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
.
2 of traditional Chinese medicine
.
According to the data from Minet.
com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
.
Source: CDE official website
Psoralea total glycosides capsule is a new orthopaedic traditional Chinese medicine.
It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
), which has the effect of warming kidney and helping yang.
Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
.
It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
), which has the effect of warming kidney and helping yang.
Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
.
According to the data of Minet.
com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
.
com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
.
Class 1 new drugs of traditional Chinese medicine for the musculoskeletal system declared for marketing/clinical in 2020
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to data from Minet.
com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
in China will exceed 30 billion yuan .
Hospital Hospital Hospital Pharmacy Pharmacy Pharmacycom, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
in China will exceed 30 billion yuan .
In the Chinese patent medicine terminal of physical pharmacies in Chinese cities, it is expected that in 2021, the sales volume of five categories of drugs will exceed 10 billion yuan, and the musculoskeletal system Chinese patent medicine is one of them
.
medicines medicines medicines.
2021E Top 5 products of Chinese patent medicines for musculoskeletal system in Chinese urban physical pharmacies
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
Judging from the ranking of Chinese patent medicine products in the musculoskeletal system, the total market share of TOP5 products exceeds 30%, of which Shujin Jianyao Pills topped the list with sales of over 1 billion yuan
.
.
